TRAVEL

A study reveals changes in proteins key to the development of Alzheimer’s disease



study Foundation for Health Promotion and Biomedical Research of the Valencian Community (Fisabio), Agency to rely on Ministry of Health Global public health, you have discovered molecular modifications that can affect the function of the proteins acetylcholinesterase (AChE) and presnillin 1 (PS1), both of which are associated with Alzheimer’s disease, as reported by the Department of Health. The study, conducted by the Alzheimer’s Disease Research Group, led by Altering Molecular Mechanisms Maria Salud Garcia Aylon in it Elche University General Hospitalhas been published in the prestigious International Journal of Multiple Sclerosis Care (IJMSC).

in it cognitive decline Associated with Alzheimer’s disease, the part of the nervous system that contains the AChE protein plays a major role. Therefore, AChE is a target of some drugs It is currently given to Alzheimer’s patients for Slow cognitive decline. However, the resulting cognitive improvement It is valid only for a limited period of time. The proper functioning of AChE, as well as that its levels are adequate in the brain and other organs, depends, among other things, on a biochemical process called glycosylation, in which the protein achieves its final structure and properly positions itself in its functional site.

The study analyzed this process in brain samples from Alzheimer’s patients and the results showed changes in the pathology that could be related to loss of protein activity AChE in Alzheimer’s patients. The research team described that a large portion of the inactive protein presents a glycosylation binding quite different from a functional protein, and may be related to the development of pathology.

See also  Ellos no siguen un patrón: cinco jóvenes que cosen para expresarse con la moda

disease variants

In addition, work has shown that this altered glycosylation binding of AChE varies between Two different types of Alzheimer’s disease: fashionable and intermittent. Familial Alzheimer’s disease has a genetic component as it occurs due to Genetic mutationsThis can be passed on to the offspring. In contrast, in the development of Alzheimer’s disease intermittentmost commonly, does not contain a file Specific behavioral science and different factors may influence.

In this study, samples from familial Alzheimer’s disease caused by mutations in the PS1 gene were used, which allowed us to confirm an alternative and less known function of this protein. This job consists of Participation in the correct maturation of other proteins and enabling it to be located correctly and to perform its function effectively. Thus, the work also concludes that alterations in PS1 will affect AChE maturation and function, contributing, again, to the development of pathology.

Both results are indicative of this Learn more about the changes Which presents the AChE protein and the role of PS1 in Alzheimer’s disease and may contribute to it Design of new treatment strategies more selective.

“This represents a major advance in the knowledge of Alzheimer’s disease. We have shown how the AChE protein It is affected differently in each of the disease Alzheimer’s disease sporadic as in family caused by PS1 mutations & rdquor;Maria Salud Garcia Aylon, Vesabio Researcher at Elche General University Hospital and Neurosciences Institute of Universidad Miguel Hernandez CSIC (IN, UMH-CSIC) confirmed.

Related news

In addition, he added, “the same phenomenon It can co-occur with other PS1-regulated proteins and is implicated in pathology, a fact that suggests that one must be careful in designing treatments and discern the effects that have They can be opposites of both forms of pathology”, concluded Garcia Aylon, lead author of the article.

See also  The "Nobody Lives Here" actor who must retire due to suffering from Parkinson's disease

This work was carried out in collaboration with Javier Saez Valero from IN, UMH-CSIC and group principal investigator in the Center for Retinal Biomedical Research in Neurodegenerative Diseases (CiberNED). Allum, MD, chair of the Department of Neurology, also participated in the study. Victor Barbera Genetic Counseling Unit and Pre-Doctoral Researcher Maria de los Angeles Cortes, Fisabio Research Staff at Elche General University Hospital. The research was funded by the Carlos III Institute of Health (ISCIII, project PI17/00261), co-financed by the European Regional Development Fund (Feder, “A Way to Make Europe”) and by Ciberned, ISCIII.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button